share_log

RBC Capital Reiterates Outperform on Viridian Therapeutics, Maintains $44 Price Target

RBC Capital Reiterates Outperform on Viridian Therapeutics, Maintains $44 Price Target

RBC Capital重申Viridian Therapeutics的買入評級,維持44美元目標價。
Benzinga ·  12/06 00:05  · 評級/大行評級

RBC Capital analyst Gregory Renza reiterates Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and maintains $44 price target.

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論